CLINICAL_TRIALS ClinicalTrials.gov record update

GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03214666
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:54.566710+00:00
Published At: 2022-11-10T00:00:00+00:00
Record Updated At: 2022-11-10
Results Posted At: 2022-11-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High-risk Myelodysplastic Syndromes", "Acute Myelogenous Leukemia", "Systemic Mastocytosis", "Mast Cell Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-11-10"
protocolSection.identificationModule.nctId: "NCT03214666"
protocolSection.identificationModule.officialTitle: "GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE\u00ae) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-11-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.